Nicox receives FDA approval of ZERVIATE (cetirizine ophthalmic solution) 0.24%
Sophia Antipolis, France Read more
- First approved US NDA for Nicox
- First topical ocular formulation of the antihistamine cetirizine
- U.S. patent protection until at least 2030
- Partnering discussions underway for U.S. commercialization rights
Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that the U.S.
Nicox to present at the 2017 BIO International Convention
15/06/2017Nicox announces the issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new shares awarded to former Aciex shareholders following the US FDA’s approval of the new drug application in the US for ZERVIATE (cetirizine ophthalmic solution) 0.24%.
08/06/2017Nicox’s Extraordinary Shareholder Meeting on May 30, 2017